{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:09:11Z","timestamp":1773356951608,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.clinthera.2010.08.004","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T08:45:34Z","timestamp":1288082734000},"page":"1674-1680","source":"Crossref","is-referenced-by-count":10,"title":["The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study"],"prefix":"10.1016","volume":"32","author":[{"given":"Kun-Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-Qiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.08.004_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1345\/aph.1C197","article-title":"Olmesartan medoxomil: The seventh angiotensin receptor antagonist","volume":"37","author":"Gardner","year":"2003","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.clinthera.2010.08.004_bib2","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1124\/dmd.107.017459","article-title":"Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor","volume":"35","author":"Yamada","year":"2007","journal-title":"Drug Metab Dispos."},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2010.08.004_bib3","doi-asserted-by":"crossref","first-page":"A21","DOI":"10.1016\/S0149-2918(04)90142-7","article-title":"Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?","volume":"26","author":"Wehling","year":"2004","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.08.004_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.jhh.1002241","article-title":"Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: An update","volume":"21","author":"Chrysant","year":"2007","journal-title":"J Hum Hypertens."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.08.004_bib6","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.jhh.1001391","article-title":"The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview","volume":"16","author":"Brunner","year":"2002","journal-title":"J Hum Hypertens."},{"key":"10.1016\/j.clinthera.2010.08.004_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0091270008322176","article-title":"Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination","volume":"48","author":"Rohatagi","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.08.004_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10038-008-0324-9","article-title":"Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLC01B1 polymorphism","volume":"53","author":"Suwannakul","year":"2008","journal-title":"J Hum Genet."},{"key":"10.1016\/j.clinthera.2010.08.004_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10157-008-0067-0","article-title":"Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: Little effect of dialysis upon its pharmacokinetics","volume":"13","author":"Tanaka","year":"2009","journal-title":"Clin Exp Nephrol."},{"key":"10.1016\/j.clinthera.2010.08.004_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/0091270008317847","article-title":"Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil","volume":"48","author":"Rohatagi","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.08.004_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00044011-200626010-00004","article-title":"Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects","volume":"26","author":"Kreutz","year":"2006","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.clinthera.2010.08.004_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/10641960600946171","article-title":"Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers","volume":"28","author":"Huber","year":"2006","journal-title":"Clin Exp Hypertens."},{"key":"10.1016\/j.clinthera.2010.08.004_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2165\/00003088-200544120-00011","article-title":"Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil, in healthy volunteers and hypertensive patients","volume":"44","author":"Yoshihara","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2010.08.004_bib14","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J Hypertens Suppl."},{"key":"10.1016\/j.clinthera.2010.08.004_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/00912700122010393","article-title":"Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects","volume":"41","author":"Schwocho","year":"2001","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.08.004_bib16","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00004872-200106001-00005","article-title":"Olmesartan medoxomil: Influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil","volume":"19","author":"von Bergmann","year":"2001","journal-title":"J Hypertens Suppl."},{"key":"10.1016\/j.clinthera.2010.08.004_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1472-8206.2009.00720.x","article-title":"Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects","volume":"23","author":"Bolbrinker","year":"2009","journal-title":"Fundam Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.08.004_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2133\/dmpk.24.376","article-title":"Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: A population pharmacokinetic\/pharmacodynamic analysis","volume":"24","author":"Tanigawara","year":"2009","journal-title":"Drug Metab Pharmacokinet."},{"key":"10.1016\/j.clinthera.2010.08.004_bib19","first-page":"323","article-title":"Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations","volume":"64","author":"Jiang","year":"2009","journal-title":"Pharmazie."},{"key":"10.1016\/j.clinthera.2010.08.004_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jchromb.2007.05.049","article-title":"Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"856","author":"Liu","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"10.1016\/j.clinthera.2010.08.004_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/abio.2000.4840","article-title":"Real-time monitoring of metabolic reactions by microdialy-sis in combination with tandem mass spectrometry: Hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines","volume":"287","author":"Kobayashi","year":"2000","journal-title":"Anal Biochem."},{"key":"10.1016\/j.clinthera.2010.08.004_bib22","first-page":"544","article-title":"Simultaneous determination of olmesartan medoxomil and irbesartan and hydrochlorothiazide in pharmaceutical formulations and human serum using high performance liquid chromatography","volume":"26","author":"Sultana","year":"2008","journal-title":"Se Pu."},{"key":"10.1016\/j.clinthera.2010.08.004_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.chroma.2005.10.077","article-title":"Comparison of ultraperformance liquid chromatography and high-performance liquid chromatography for the determination of priority pesticides in baby foods by tandem quadrupole mass spectrometry","volume":"1103","author":"Leandro","year":"2006","journal-title":"J Chromatogr A."},{"key":"10.1016\/j.clinthera.2010.08.004_bib26","series-title":"Bioequivalence Studies in Drug Development: Methods and Applications","author":"Hauschke","year":"2007"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000264X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000264X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T07:25:00Z","timestamp":1544167500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181000264X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S014929181000264X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.08.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}